Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Dec '20	Jan '21	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jul '22	Sep '22	Dec '22	Dec '23
asset turnover										0.08 -	0.05 -
cash conversion cycle										51.04 -	175.60 -
cash per share			29.67 -	0.02 99.93%	0.01 60.67%	0.17 2,144.04%	0.13 27.58%	0.01 90.84%		0.09 -	0.17 -
company equity multiplier	14.29 -	14.29 0%	1.14 92.00%	1.15 0.32%	1.12 2.67%	1.20 7.04%	1.18 1.17%	1.17 1.11%		1.71 -	1.67 -
days of inventory outstanding										56.78 -	283.11 -
days of payables outstanding				31.59 -	9.31 70.52%	2.69 71.11%	36.99 1,275.12%			25.32 -	142.80 -
days of sales outstanding										19.58 -	35.29 -
dividend yield
ebit per revenue									-0.15 -	-0.60 -	-0.43 -
ebt per ebit			10.07 -	7.70 23.60%	-12.02 256.22%	2.38 119.80%	-0.76 131.71%	-0.63 16.67%	1.22 294.29%	2.56 -	1.53 -
effective tax rate			-0.90 -	-0.87 3.40%	-1.08 24.49%	-0.58 46.45%	-2.32 300.75%	-2.68 15.39%	-0.06 97.64%	0.05 -	-0.03 -
enterprise value multiple			119.52 -	368.61 208.42%	-46.76 112.69%	27.39 158.57%	-7.79 128.44%	-6.83 12.32%	0.00 100.00%	-37.39 -	-161.19 -
fixed asset turnover										3.64 -	3.11 -
free cash flow per share			-0.00 -	-0.01 201.58%	-0.01 13.55%	0.04 441.16%	-0.05 217.63%	-0.18 283.15%		0.43 -
gross profit margin									0.47 -	0.04 -	0.67 -
interest coverage			-0.11 -	-0.15 35.50%	0.08 151.42%	-0.72 1,043.16%	0.57 178.68%	-17.09 3,100.17%	-3.53 79.37%	-5.65 -
inventory turnover										1.58 -	0.32 -
long term debt to capitalization						0.01 -	0.01 1.03%	0.01 38.42%		0.20 -	0.21 -
net income per ebt			1 -	1 0%	1 0%	1 0%	3.32 232.44%	3.68 10.76%	1.08 70.63%	0.77 -	1.09 -
net profit margin									-0.20 -	-1.19 -	-0.72 -
operating cash flow per share			-0.00 -	-0.01 201.58%	-0.01 13.55%	0.04 441.16%	-0.05 217.63%	-0.18 283.15%		0.43 -
operating cycle										76.36 -	318.40 -
operating profit margin									-0.15 -	-0.60 -	-0.43 -
payables turnover				2.85 -	9.67 239.27%	33.46 246.15%	2.43 92.73%			3.56 -	0.63 -
pretax profit margin									-0.19 -	-1.55 -	-0.66 -
price fair value			0.38 -	1.42 274.94%	1.36 3.98%	0.30 78.33%	0.29 1.43%	0.25 12.83%		1.53 -	2.14 -
receivables turnover										4.60 -	2.55 -
return on assets			-0.00 -	-0.00 31.30%	0.02 600.86%	-0.06 349.93%	0.03 151.74%	0.03 1.57%		-0.10 -	-0.04 -
return on capital employed			-0.00 -	-0.00 71.62%	-0.00 220.64%	-0.02 1,163.12%	-0.01 50.72%	-0.01 9.85%		-0.05 -	-0.02 -
return on equity			-0.00 -	-0.01 31.72%	0.03 587.47%	-0.07 367.53%	0.03 151.14%	0.03 0.44%	309.39 898,671.35%	-0.17 -	-0.06 -
total debt to capitalization						0.01 -	0.01 1.03%	0.01 38.42%		0.22 -	0.22 -

NASDAQ:WALD

Waldencast

Last Close

3.47

26/07 20:00

Market Cap

456.93M

Beta: -

Volume Today

73.17K

Avg: 5.58K

PE Ratio

−2.75

PFCF: 366.52

Preview